2566 — Hangzhou Jiuyuan Genetic Biopharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapContrarian

Market Cap
HK$1.46bn
Enterprise Value
HK$899.89m
Revenue
CNY1.31bn

Annual income statement for Hangzhou Jiuyuan Genetic Biopharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,307	1,125	1,287	1,369	1,306
Cost of Revenue
Gross Profit	950	854	991	1,082	1,054
Selling / General / Administrative Expenses
Research And Development
Other Operating Expenses
Total Operating Expenses	1,170	1,065	1,143	1,193	1,139
Operating Profit	137	60.5	144	176	167
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	128	51.4	135	169	162
Provision for Income Taxes
Net Income After Taxes	119	59.9	120	139	138
Net Income Before Extraordinary Items
Net Income	119	59.9	120	139	138
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	119	59.9	120	139	138
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.488	0.245	0.53	0.803	0.574
Dividends per Share